PT3188725T - Composições farmacêuticas compreendendo levodopa, um inibidor de descarboxílase de dopamina e um inibidor de comt, e método de administração destes - Google Patents
Composições farmacêuticas compreendendo levodopa, um inibidor de descarboxílase de dopamina e um inibidor de comt, e método de administração destesInfo
- Publication number
- PT3188725T PT3188725T PT158388009T PT15838800T PT3188725T PT 3188725 T PT3188725 T PT 3188725T PT 158388009 T PT158388009 T PT 158388009T PT 15838800 T PT15838800 T PT 15838800T PT 3188725 T PT3188725 T PT 3188725T
- Authority
- PT
- Portugal
- Prior art keywords
- inhibitor
- levodopa
- administration
- pharmaceutical compositions
- dopamine decarboxylase
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 229940123736 Decarboxylase inhibitor Drugs 0.000 title 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 title 1
- 239000003954 decarboxylase inhibitor Substances 0.000 title 1
- 229960003638 dopamine Drugs 0.000 title 1
- 229960004502 levodopa Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1451034A SE538425C2 (en) | 2014-09-04 | 2014-09-04 | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| SE1550344 | 2015-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3188725T true PT3188725T (pt) | 2021-01-27 |
Family
ID=55440194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT202000709T PT3782617T (pt) | 2014-09-04 | 2015-09-04 | Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona |
| PT158388009T PT3188725T (pt) | 2014-09-04 | 2015-09-04 | Composições farmacêuticas compreendendo levodopa, um inibidor de descarboxílase de dopamina e um inibidor de comt, e método de administração destes |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT202000709T PT3782617T (pt) | 2014-09-04 | 2015-09-04 | Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10071069B2 (pt) |
| EP (3) | EP3188725B1 (pt) |
| JP (2) | JP6622310B2 (pt) |
| CN (1) | CN107072973A (pt) |
| AU (3) | AU2015312430B2 (pt) |
| CA (2) | CA3175785A1 (pt) |
| DK (2) | DK3782617T3 (pt) |
| ES (2) | ES2973289T3 (pt) |
| FI (1) | FI3782617T3 (pt) |
| HR (2) | HRP20240314T1 (pt) |
| HU (2) | HUE052857T2 (pt) |
| PL (2) | PL3188725T3 (pt) |
| PT (2) | PT3782617T (pt) |
| RS (1) | RS65337B1 (pt) |
| SI (2) | SI3782617T1 (pt) |
| WO (1) | WO2016036308A1 (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE052857T2 (hu) | 2014-09-04 | 2021-05-28 | Lobsor Pharmaceuticals Ab | Levodopat, egy dopamin dekarboxiláz inhibitort és egy COMT inhibitort tartalmazó gyógyászati készítmények, és azok adagolási módszerei |
| WO2016083863A1 (en) * | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
| CN113197851A (zh) | 2015-05-06 | 2021-08-03 | 辛纳吉勒公司 | 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法 |
| US10555922B2 (en) | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| AU2017250002B2 (en) | 2016-04-11 | 2022-12-22 | University Of Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
| WO2018017850A1 (en) * | 2016-07-20 | 2018-01-25 | Abbvie Inc. | Levodopa and carbidopa intestinal gel and methods of use |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| UA124124C2 (uk) | 2017-02-13 | 2021-07-21 | Баєр Енімал Хелс Гмбх | Рідка композиція, що містить прадофлоксацин |
| WO2019129120A1 (en) * | 2017-12-28 | 2019-07-04 | Rpxds Co., Ltd | Tolcapone for prevention and/or treatment of obesity and related metabolic diseases |
| JP7485874B2 (ja) * | 2018-03-23 | 2024-05-17 | イントランス・メディカル・システムズ・インコーポレイテッド | 神経変性障害の治療のための医薬組成物の連続的投与 |
| EP3593819A1 (en) * | 2018-07-10 | 2020-01-15 | Medday Pharmaceuticals | Compositions for therapeutic uses containing 5-htp and carbidopa |
| JP7506371B2 (ja) | 2020-01-20 | 2024-06-26 | 国立大学法人浜松医科大学 | ドーパミン減少抑制剤 |
| CN111643493B (zh) * | 2020-05-26 | 2023-01-10 | 上海京新生物医药有限公司 | 一种高浓度左旋多巴制剂及其制备方法及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004348D0 (en) | 1990-02-27 | 1990-04-25 | Orion Yhtymae Oy | New use of catechol derivatives and their physiologically acceptable salts and esters |
| SE9203594D0 (sv) | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| US6376545B1 (en) * | 1998-11-10 | 2002-04-23 | Teva Pharmaceutical Industries, Ltd. | Dispersible compositions containing L-DOPA ethyl ester |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US20100221321A1 (en) | 2003-02-27 | 2010-09-02 | Innercap Technologies, Inc. | Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions |
| CN1845728B (zh) * | 2003-08-29 | 2013-06-19 | 转化医药公司 | 包含左旋多巴和卡比多巴的药物组合物 |
| US20050070608A1 (en) | 2003-08-29 | 2005-03-31 | Julius Remenar | Pharmaceutical compositions and method of using levodopa and carbidopa |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US20060222703A1 (en) | 2005-04-01 | 2006-10-05 | Iprbox Oy | Pharmaceutical composition and preparation method thereof |
| UA95954C2 (ru) | 2006-05-31 | 2011-09-26 | Солвей Фармасьютикалс Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
| WO2008053297A2 (en) | 2006-10-30 | 2008-05-08 | Wockhardt Research Centre | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa |
| RU2485947C2 (ru) * | 2008-02-06 | 2013-06-27 | Вокхардт Рисерч Сентер | Фармацевтические композиции энтакапона, леводопы и карбидопы с улучшенной биодоступностью |
| MX364974B (es) * | 2009-05-19 | 2019-05-16 | Neuroderm Ltd | Composiciones para la administracion continua de inhibidores de dopa descarboxilasa. |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| ES2776734T3 (es) | 2010-11-15 | 2020-07-31 | Neuroderm Ltd | Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello |
| WO2012147099A1 (en) | 2011-04-25 | 2012-11-01 | Suven Nishtaa Pharma Pvt. Ltd. | Pharmaceutical compositions of levodopa, carbidopa and entacapone |
| CA2904838C (en) | 2013-03-13 | 2021-03-16 | Neuroderm Ltd. | Method for treatment of parkinson's disease |
| HUE052857T2 (hu) | 2014-09-04 | 2021-05-28 | Lobsor Pharmaceuticals Ab | Levodopat, egy dopamin dekarboxiláz inhibitort és egy COMT inhibitort tartalmazó gyógyászati készítmények, és azok adagolási módszerei |
| SE538425C2 (en) | 2014-09-04 | 2016-06-21 | Lobsor Pharmaceuticals Ab | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| US10555922B2 (en) | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
-
2015
- 2015-09-04 HU HUE15838800A patent/HUE052857T2/hu unknown
- 2015-09-04 RS RS20240276A patent/RS65337B1/sr unknown
- 2015-09-04 ES ES20200070T patent/ES2973289T3/es active Active
- 2015-09-04 SI SI201531992T patent/SI3782617T1/sl unknown
- 2015-09-04 FI FIEP20200070.9T patent/FI3782617T3/fi not_active Application Discontinuation
- 2015-09-04 CN CN201580050984.7A patent/CN107072973A/zh active Pending
- 2015-09-04 SI SI201531474T patent/SI3188725T1/sl unknown
- 2015-09-04 EP EP15838800.9A patent/EP3188725B1/en active Active
- 2015-09-04 AU AU2015312430A patent/AU2015312430B2/en active Active
- 2015-09-04 WO PCT/SE2015/050939 patent/WO2016036308A1/en active Application Filing
- 2015-09-04 PT PT202000709T patent/PT3782617T/pt unknown
- 2015-09-04 ES ES15838800T patent/ES2844500T3/es active Active
- 2015-09-04 CA CA3175785A patent/CA3175785A1/en active Pending
- 2015-09-04 DK DK20200070.9T patent/DK3782617T3/da active
- 2015-09-04 CA CA2959307A patent/CA2959307C/en active Active
- 2015-09-04 PL PL15838800T patent/PL3188725T3/pl unknown
- 2015-09-04 JP JP2017533154A patent/JP6622310B2/ja active Active
- 2015-09-04 US US15/507,959 patent/US10071069B2/en active Active
- 2015-09-04 EP EP23219005.8A patent/EP4356907A1/en active Pending
- 2015-09-04 HR HRP20240314TT patent/HRP20240314T1/hr unknown
- 2015-09-04 DK DK15838800.9T patent/DK3188725T3/da active
- 2015-09-04 PT PT158388009T patent/PT3188725T/pt unknown
- 2015-09-04 EP EP20200070.9A patent/EP3782617B1/en active Active
- 2015-09-04 PL PL20200070.9T patent/PL3782617T3/pl unknown
- 2015-09-04 HU HUE20200070A patent/HUE066097T2/hu unknown
-
2018
- 2018-08-03 US US16/054,392 patent/US10786472B2/en active Active
-
2019
- 2019-11-21 JP JP2019210309A patent/JP6889231B2/ja active Active
-
2020
- 2020-08-13 US US16/992,824 patent/US11413262B2/en active Active
- 2020-09-23 AU AU2020239682A patent/AU2020239682B2/en active Active
-
2021
- 2021-01-07 HR HRP20210025TT patent/HRP20210025T1/hr unknown
-
2022
- 2022-01-18 AU AU2022200291A patent/AU2022200291B2/en active Active
- 2022-06-07 US US17/834,839 patent/US20220362193A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3188725T (pt) | Composições farmacêuticas compreendendo levodopa, um inibidor de descarboxílase de dopamina e um inibidor de comt, e método de administração destes | |
| IL260025A (en) | A drug for the treatment of influenza characterized by the combination of a cap-dependent endonuclease inhibitor with an anti-influenza drug | |
| HK1256997A1 (zh) | Tyk2抑制劑及其用途 | |
| HK1248690A1 (zh) | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 | |
| HK1251466A1 (zh) | 包含pi3k抑制劑和hdac抑制劑的組合物 | |
| ZA201803485B (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
| IL247668A0 (en) | Preparations that include dopa decarboxylase inhibitors | |
| PL3884939T3 (pl) | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania | |
| PL3426244T3 (pl) | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania | |
| IL258513B (en) | History of quinoxaline and pyridopyrazine as pi3k inhibitors in the cell | |
| IL247921A0 (en) | Glutaminase inhibitor compounds, preparations containing them and their uses | |
| EP3771709C0 (en) | CREATINE PRODRUGS, COMPOSITIONS CONTAINING THEM AND METHODS OF USE THEREOF | |
| EP3272742A4 (en) | Histone deacetylase inhibitor, and preparation method and use thereof | |
| IL274701A (en) | Promote drugs, compositions and methods of their use | |
| IL252752A0 (en) | Pharmaceutical preparations containing a combination of pyridazine and egfr inhibitor | |
| IL251162A0 (en) | Monoamine oxidase-B inhibitors and rehabilitation | |
| HK1244224B (zh) | Mek抑制劑的藥物組合物及其製備方法 |